An inhibitor of ecto-5’-nucleotidase
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Adenosine 5'-methylenediphosphate (hydrate)

Item No. 34504

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
adenosine, 5′-[hydrogen P-(phosphonomethyl)phosphonate], hydrate
Synonyms
  • Adenosine 5'-(α,β-methylene)diphosphate
  • AMP-CP
  • APCP
  • 5'-APCP
Molecular Formula
C11H17N5O9P2 • XH2O
Formula Weight
425.2
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
Water: 50 mg/ml
SMILES
O[C@H]1[C@](O[C@@H]([C@H]1O)COP(CP(O)(O)=O)(O)=O)([H])N2C3=NC=NC(N)=C3N=C2.O
InChi Code
InChI=1S/C11H17N5O9P2.H2O/c12-9-6-10(14-2-13-9)16(3-15-6)11-8(18)7(17)5(25-11)1-24-27(22,23)4-26(19,20)21;/h2-3,5,7-8,11,17-18H,1,4H2,(H,22,23)(H2,12,13,14)(H2,19,20,21);1H2/t5-,7-,8-,11-;/m1./s1
InChi Key
RWQQCDRKMWZMRR-YCSZXMBFSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $54

    Add

    5 mg

    $185

    Add

    10 mg

    $290

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Adenosine 5'-methylenediphosphate is an inhibitor of ecto-5’-nucleotidase, also known as CD73, with a Ki value of 37 nM.1 It inhibits cAMP accumulation induced by adenosine 5'-monophosphate (AMP; Item No. 21094), adenosine 5'-diphosphate (ADP; Item Nos. 16778 | 21121), or adenosine 5'-triphosphate (ATP; Item No. 14498) but not adenosine (Item No. 21232) in VA-13 human fibroblasts when used at a concentration of 100 µM. Adenosine 5'-methylenediphosphate reduces proliferation of U138MG glioma cells, as well as inhibits the invasion and migration of MHCC97H hepatocellular carcinoma (HCC) cells in a migration assay.2,3 It increases tumor infiltration of CD3+CD8+ T cells and reduces tumor growth in a K1735 murine melanoma model when administered at a dose of 400 µg/mouse.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Bruns, R.F. Adenosine receptor activation by adenine nucleotides requires conversion of the nucleotides to adenosine. Naunyn Schmiedebergs Arch. Pharmacol. 315(1), 5-13 (1980).

    2. Braganhol, E., Tamajusuku, A.S.K., Bernardi, A., et al. Ecto-5′-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line. Biochim. Biophys. Acta 1770(9), 1352-1359 (2007).

    3. Shali, S., Yu, J., Zhang, X., et al. Ecto‐5′‐nucleotidase (CD73) is a potential target of hepatocellular carcinoma. J. Cell Physiol. 234(7), 10248-10259 (2018).

    4. Forte, G., Sorrentino, R., Montinaro, A., et al. Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J. Immunol. 189(5), 2226-2233 (2021).